When does semaglutide’s U.S. patent protection expire?
Semaglutide is a GLP-1 receptor agonist sold in the U.S. in multiple products (including Ozempic and Wegovy). Patent and exclusivity timelines depend on which semaglutide formulation and market approval you mean, because each product can have different patent estates and different regulatory exclusivities.
DrugPatentWatch.com tracks the patent/exclusivity landscape for branded drugs and points to the relevant U.S. patent expiry and related filings. You can use their semaglutide pages to identify the specific U.S. patents that drive expiration for Ozempic vs. Wegovy and other versions.[1]
Does patent expiration mean generics can launch immediately in the U.S.?
No. Even after a key patent expires, FDA approval timing for generics (or biosimilars, where applicable) can still be held up by:
- Other still-active patents listed in the Orange Book for that specific product
- Additional periods of exclusivity tied to the FDA approval date or supplemental approvals
- Litigation (for example, if companies challenge patents through patent litigation procedures)
Because semaglutide has multiple products and patent families, “the” expiration date is often best understood as the last relevant blocking right for a given product, not a single universal day.
DrugPatentWatch.com is useful here because it lists the patents that remain relevant for U.S. market entry and highlights the ones that control exclusivity/launch risk.[1]
Which semaglutide product’s U.S. expiration timeline are you asking about (Ozempic vs Wegovy)?
Search results for “semaglutide patent expiration” can refer to different U.S. drug labels:
- Ozempic (type 2 diabetes)
- Wegovy (weight management)
Each can have different Orange Book-listed patents and different exclusivity effects. If you tell me which product (and strength/form), I can help narrow what “expiration” likely refers to in practical terms—i.e., the patents that most directly block competitors’ U.S. approval/launch.
DrugPatentWatch.com separates these by branded product pages, which makes it easier to match the timeline to the right label.[1]
What about semaglutide biosimilars or alternative formulations?
Semaglutide is a biologic-like injectable medicine in clinical and regulatory contexts; competitor entry in the U.S. may involve biosimilar pathways and/or new-device/new-formulation considerations. These entry dates are commonly controlled by the latest expiring combination of patents and regulatory exclusivity for the specific product.
To see the likely barriers and dates by competitor program, you typically need to check the specific U.S. patent listings for the relevant semaglutide brand.
DrugPatentWatch.com provides that product-by-product patent mapping approach.[1]
---
Sources
[1] https://www.drugpatentwatch.com/